fda bpc-157 compounding safety risks advisers back first four of seven unapproved peptides under review for looser rules FDA Panel Finds a Peptide

FDA's advisory committee evaluated BPC-157 for ulcerative colitis in July 2026 an evaluation of a proposed use, not a study of it

Front Pub Health (2020)

Petersburg Institute of Bioregulation and Gerontology, it has since become one of the most referenced peptides in longevity-related science

At elevated temperatures, even a few degrees above refrigeration, the rate of hydrolysis measurably increases per Arrhenius kinetics

This immune-boosting effect is particularly important for maintaining health and vitality in the later stages of life

doi:10.1042/bj20031975 Simmaco M, Mignogna G, Canofeni S, Miele R, Mangoni ML, Temporins BD